Focus nets clearance for CardioMatch
Focus Medical has received Food and Drug Administration 510(k) clearance for CardioMatch, a 3-D image analysis software program designed to improve the specificity of a myocardial perfusion study. The Belmont, CA-based company is also in final
Focus Medical has received Food and Drug Administration 510(k) clearance for CardioMatch, a 3-D image analysis software program designed to improve the specificity of a myocardial perfusion study. The Belmont, CA-based company is also in final negotiations with a major medical university and hospital group in Northern California to perform a large clinical validation study using CardioMatch.
CardioMatch has been cleared as a cardiac diagnostic software program to quantitatively analyze myocardial perfusion in patients injected with Cardiolite or thallium-201 following a rest/stress SPECT acquisition protocol. The company unveiled CardioMatch at the annual meeting of the Society of Nuclear Medicine in June (SCAN Special Report 6/97).
Focus plans to continue to pursue new applications for its image analysis technology. The firm expects to file a 510(k) application in the fourth quarter for PneumoMatch, which is targeted at the early detection, quantitation, and 3-D visualization of pulmonary embolism. Additional neurological and oncologic applications are also on the drawing board.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
